1. U.S. drug policy is determined by the Controlled Substances Act, which categorizes drugs under different schedules and criteria.
2. Speculation about changes in marijuana classification by President Trump led to brief stock increases for major cannabis companies like Trulieve Cannabis, Curaleaf Holdings, Tilray Brands, and Green Thumb Industries.
3. Trump’s executive order reclassifies marijuana from a Schedule I to a Schedule III drug, which could benefit cannabis companies in terms of research, partnerships with pharmaceutical companies, and lower taxes.
4. Despite the reclassification, the future of cannabis stocks remains uncertain, leading to ongoing volatility and making it a risky investment choice for long-term investors.
5. Tilray Brands was not included in the list of 10 best stocks to buy now by the Motley Fool Stock Advisor team, with a total average return of 972% compared to the S&P 500’s 193%.

Read more at Nasdaq: Everything Investors Need to Know About President Trump’s Executive Order Reclassifying Marijuana as a Lower Class of Drug